financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
Mar 4, 2024 11:01 PM

01:00 PM EST, 02/29/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target to $71 from $47 on a P/S of 7.5x, above its three-year average on good sales execution and a favorable deal pipeline, using our next-12-month sales estimate of $2.3B. We lift our FY 24 EPS view to $1.07 from $0.95 and FY 25's to $1.33 from $1.21. NTNX posted Q2 sales of $565.2M, above consensus by $14.8M, while non-GAAP EPS of $0.46 beat by $0.17. Revenue rose 16.2% Y/Y from solid Subscription revenue growth (+18% Y/Y) as ACV billings outperformed, up 23% Y/Y, from higher-than-anticipated renewals. We note NTNX's commentary around a continued uncertain macro environment, and longer average sales cycles, which likely impacted contract duration of 2.8 years in Q2, lower than Q1. However, these results reflect the firm's strong execution in securing and keeping pace with renewals and expansion deals, as well as maintaining healthy pricing levels in spite of these challenges. Its upbeat guidance and a higher mix of large deals in the pipeline further support our positive view of the business.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Raises Opinion On Health Care To Marketweight From Underweight
Research Alert: CFRA Raises Opinion On Health Care To Marketweight From Underweight
Oct 8, 2025
01:40 PM EDT, 10/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Pfizer Inc. (PFE 26 ****) and the U.S. government struck the first Most Favored Nation (MFN) drug pricing deal to lower drug prices in the U.S., we see policy...
Research Alert: CFRA Lowers Opinion On Real Estate To Underweight From Marketweight
Research Alert: CFRA Lowers Opinion On Real Estate To Underweight From Marketweight
Oct 8, 2025
02:20 PM EDT, 10/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We are lowering our opinion on the Real Estate sector to underweight given its vulnerability to potential disappointment if Fed rate cuts prove less aggressive than market expectations, combined with...
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Ferrari N.v.
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Ferrari N.v.
Oct 9, 2025
10:15 AM EDT, 10/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target at $350, based on a 2026 P/E of 30x, a justified discount to RACE's 10-year average forward P/E multiple of 40x. Our adjusted EPS estimates...
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Pepsico, Inc.
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Pepsico, Inc.
Oct 9, 2025
01:45 PM EDT, 10/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target of $170, based on a 2026 P/E of 20.2x, a justified discount to PEP's five-year mean forward P/E of 23.0x. We maintain our adjusted EPS...
Copyright 2023-2026 - www.financetom.com All Rights Reserved